Se connecter

Bibliographies thématiques / HIV (Viruses) Gene therapy

Sommaire

Articles de revues
Thèses
Livres
Chapitres de livres
Actes de conférences

Littérature scientifique sur le sujet « HIV (Viruses) Gene therapy »

Auteur : Grafiati

Publié le 4 juin 2021

Mis à jour le 1 février 2022

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « HIV (Viruses) Gene therapy ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "HIV (Viruses) Gene therapy"

1

Hu, JinTing, YeWen Feng, Ping Ma, and Yu Lai. "Coreceptor-Based Hematopoietic Stem Cell Gene Therapy for HIV Disease." Current Stem Cell Research & Therapy 14, no. 7 (September 23, 2019): 591–97. http://dx.doi.org/10.2174/1574888x14666190523094556.

Texte intégral

Résumé :

: Combination antiretroviral therapy (cART) has significantly reduced the mortality rate and morbidity, and has increased the life expectancy of the human immunodeficiency virus (HIV) infected patients. However, the current cART is incapable of eradicating viruses from the human body, and HIV remains one of the most notorious viruses mankind has ever faced. HIV-1 enters target cells through the binding of gp120 viral protein to a CD4 receptor and then to a coreceptor, C-C chemokine receptor 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4). Individuals homozygous for a 32-bp deletion in the

Styles APA, Harvard, Vancouver, ISO, etc.

2

Weinberger, Leor S., David V. Schaffer, and Adam P. Arkin. "Theoretical Design of a Gene Therapy To Prevent AIDS but Not Human Immunodeficiency Virus Type 1 Infection." Journal of Virology 77, no. 18 (September 15, 2003): 10028–36. http://dx.doi.org/10.1128/jvi.77.18.10028-10036.2003.

Texte intégral

Résumé :

ABSTRACT Recent reports confirm that, due to the presence of long-lived, latently infected cell populations, eradication of human immunodeficiency virus type 1 (HIV-1) from infected patients by using antiretroviral drugs will be exceedingly difficult. An alternative to virus eradication may be to use gene therapy to induce a pseudo-latent state in virus-producing cells, thus transforming HIV-1 into a lifelong, but manageable, virus. Conditionally replicating HIV-1 (crHIV-1) gene therapy vectors provide an avenue for subduing HIV-1 expression in infected cells (by creating a parasite, crHIV-1,

Styles APA, Harvard, Vancouver, ISO, etc.

3

Das, Atze T., Thijn R. Brummelkamp, Ellen M. Westerhout, Monique Vink, Mandy Madiredjo, René Bernards, and Ben Berkhout. "Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition." Journal of Virology 78, no. 5 (March 1, 2004): 2601–5. http://dx.doi.org/10.1128/jvi.78.5.2601-2605.2004.

Texte intégral

Résumé :

ABSTRACT Short-term assays have suggested that RNA interference (RNAi) may be a powerful new method for intracellular immunization against human immunodeficiency virus type 1 (HIV-1) infection. However, RNAi has not yet been shown to protect cells against HIV-1 in long-term virus replication assays. We stably introduced vectors expressing small interfering RNAs (siRNAs) directed against the HIV-1 genome into human T cells by retroviral transduction. We report here that an siRNA directed against the viral Nef gene (siRNA-Nef) confers resistance to HIV-1 replication. This block in replication is

Styles APA, Harvard, Vancouver, ISO, etc.

4

Bacheler, Lee, Susan Jeffrey, George Hanna, Richard D'Aquila, Lany Wallace, Kelly Logue, Beverly Cordova, et al. "Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy." Journal of Virology 75, no. 11 (June 1, 2001): 4999–5008. http://dx.doi.org/10.1128/jvi.75.11.4999-5008.2001.

Texte intégral

Résumé :

ABSTRACT Efavirenz (also known as DMP 266 or SUSTIVA) is a potent nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity and of HIV-1 replication in vitro and in vivo. Most patients on efavirenz-containing regimens have sustained antiviral responses; however, rebounds in plasma viral load have been observed in some patients in association with the emergence of mutant strains of HIV-1. Virus isolates from the peripheral blood mononuclear cells (PBMCs) of patients with such treatment failures, as well as recombinant viruses incorporating viral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Sakkhachornphop, Supachai, Sudarat Hadpech, Tanchanok Wisitponchai, Chansunee Panto, Doungnapa Kantamala, Utaiwan Utaipat, Jutarat Praparattanapan, et al. "Broad-Spectrum Antiviral Activity of an Ankyrin Repeat Protein on Viral Assembly against Chimeric NL4-3 Viruses Carrying Gag/PR Derived from Circulating Strains among Northern Thai Patients." Viruses 10, no. 11 (November 13, 2018): 625. http://dx.doi.org/10.3390/v10110625.

Texte intégral

Résumé :

Certain proteins have demonstrated proficient human immunodeficiency virus (HIV-1) life cycle disturbance. Recently, the ankyrin repeat protein targeting the HIV-1 capsid, AnkGAG1D4, showed a negative effect on the viral assembly of the HIV-1NL4-3 laboratory strain. To extend its potential for future clinical application, the activity of AnkGAG1D4 in the inhibition of other HIV-1 circulating strains was evaluated. Chimeric NL4-3 viruses carrying patient-derived Gag/PR-coding regions were generated from 131 antiretroviral drug-naïve HIV-1 infected individuals in northern Thailand during 2001–20

Styles APA, Harvard, Vancouver, ISO, etc.

6

Manisha. B. Shinde, Dr. Archana D. Kajale, Dr. Madhuri A. Channawar, and Dr. Shilpa R. Gawande. "Vector-mediated cancer gene therapy: A review." GSC Biological and Pharmaceutical Sciences 13, no. 2 (November 30, 2020): 152–65. http://dx.doi.org/10.30574/gscbps.2020.13.2.0368.

Texte intégral

Résumé :

Gene therapy is the transfer of genetic material to cure a disease or at least to improve the clinical status of a patient. One of the basic concepts of gene therapy is to transform viruses into genetic shuttles, which will deliver the gene of interest into the target cells. Safe methods have been devised to do this, using several viral and non-viral vectors. Two main approaches emerged: in vivo modification and ex vivo modification. Retrovirus, adenovirus, adenoassociated virus are suitable for gene therapeutic approaches which are based on permanent expression of the therapeutic gene. Non-vi

Styles APA, Harvard, Vancouver, ISO, etc.

7

Martinez, Miguel Angel, Maria Nevot, Ana Jordan-Paiz, and Sandra Franco. "Similarities between Human Immunodeficiency Virus Type 1 and Hepatitis C Virus Genetic and Phenotypic Protease Quasispecies Diversity." Journal of Virology 89, no. 19 (July 15, 2015): 9758–64. http://dx.doi.org/10.1128/jvi.01097-15.

Texte intégral

Résumé :

ABSTRACTHuman immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) are two highly variable RNA viruses that cause chronic infections in humans. Although HCV likely preceded the AIDS epidemic by some decades, the global spread of both viruses is a relatively recent event. Nevertheless, HCV global diversity is higher than that of HIV-1. To identify differences in mutant diversity, we compared the HIV-1 protease and HCV NS3 protease quasispecies. Three protease gene quasispecies samples per virus, isolated from a total of six infected patients, were genetically and phenotypically ana

Styles APA, Harvard, Vancouver, ISO, etc.

8

Bailey, Justin R., Ahmad R. Sedaghat, Tara Kieffer, Timothy Brennan, Patricia K. Lee, Megan Wind-Rotolo, Christine M. Haggerty, et al. "Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells." Journal of Virology 80, no. 13 (July 1, 2006): 6441–57. http://dx.doi.org/10.1128/jvi.00591-06.

Texte intégral

Résumé :

ABSTRACT Antiretroviral therapy can reduce human immunodeficiency virus type 1 (HIV-1) viremia to below the detection limit of ultrasensitive clinical assays (50 copies of HIV-1 RNA/ml). However, latent HIV-1 persists in resting CD4+ T cells, and low residual levels of free virus are found in the plasma. Limited characterization of this residual viremia has been done because of the low number of virions per sample. Using intensive sampling, we analyzed residual viremia and compared these viruses to latent proviruses in resting CD4+ T cells in peripheral blood. For each patient, we found some v

Styles APA, Harvard, Vancouver, ISO, etc.

9

Saunders, Kevin O., Lingshu Wang, M. Gordon Joyce, Zhi-Yong Yang, Alejandro B. Balazs, Cheng Cheng, Sung-Youl Ko, et al. "Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection." Journal of Virology 89, no. 16 (June 3, 2015): 8334–45. http://dx.doi.org/10.1128/jvi.00908-15.

Texte intégral

Résumé :

ABSTRACTBroadly neutralizing antibodies (bnAbs) can prevent lentiviral infection in nonhuman primates and may slow the spread of human immunodeficiency virus type 1 (HIV-1). Although protection by passive transfer of human bnAbs has been demonstrated in monkeys, durable expression is essential for its broader use in humans. Gene-based expression of bnAbs provides a potential solution to this problem, although immune responses to the viral vector or to the antibody may limit its durability and efficacy. Here, we delivered an adeno-associated viral vector encoding a simianized form of a CD4bs bn

Styles APA, Harvard, Vancouver, ISO, etc.

10

Styczyński, Jan. "ABC of viral infections in hematology: focus on herpesviruses." Acta Haematologica Polonica 50, no. 3 (September 28, 2019): 159–66. http://dx.doi.org/10.2478/ahp-2019-0026.

Texte intégral

Résumé :

AbstractViruses are a form of life that possess genes but do not have a cellular structure. Viruses do not have their own metabolism, and they require a host cell to make new products; therefore, they cannot naturally reproduce outside a host cell. The objective of this paper is to present the basic practical clinical roles of viruses in patients with hematological diseases including malignancies and non-malignan- cies, as well as those undergoing hematopoietic cell transplantation (HCT), with the focus on herpesviruses causing latent infections in severely immunocompromised patients. From the

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "HIV (Viruses) Gene therapy"

1

Fuller, Maria. "A gene transfer system derived from human immunodeficiency virus type 1 (HIV-1)." Title page, table of contents, list of abbreviations and epitome only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phf9669.pdf.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Grzybowski, Brad. "A pseudotyped viral vector : hPIV3-HIV-1." Thesis, Georgia Institute of Technology, 2003. http://hdl.handle.net/1853/20932.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Gelinas, Jean-Francois. "Enhancement of lentiviral vector production through alteration of virus-cell interactions." Thesis, University of Oxford, 2016. https://ora.ox.ac.uk/objects/uuid:9921b8b4-e2b5-4eec-9efc-6036765c8d55.

Texte intégral

Résumé :

Gene therapy is the introduction or alteration of genetic material with the intention to treat disease. To support this aim, viruses have been modified, with elements linked to viral pathogenicity removed from their genome and replaced by the genetic material to be delivered. Gene therapy vectors based on lentiviruses have many advantages, such as the ability to transduce non-dividing cells and to target specific cell types via pseudotyping. They have been successfully used in ex vivo clinical trials for several haematopoietic stem cell disorders. Lentiviral vectors, however, suffer from subst

Styles APA, Harvard, Vancouver, ISO, etc.

4

Elmén, Joacim. "Nucleic acid based therapeutic approaches /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-047-8/.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Morin, Nicolas. "Expression of mutated HIV-1 Gag-Pol proteins and their effects on virus replication and infectiousness, implications for gene therapy." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape16/PQDD_0015/MQ37152.pdf.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Mackler, Randi Michelle. "Understanding Prototype Foamy Virus Integrase Site Selection, Activity, and Stability." The Ohio State University, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=osu1542306356468134.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

ALVES, Neyla Maria Pereira. "Influência de polimorfismos de base única (SNPs) no gene do receptor de vitamina D (VDR) na resposta à Terapia Antirretroviral (TARV) de pessoas vivendo com Vírus da Imunodeficiência Humana tipo 1 (HIV-1)." Universidade Federal de Pernambuco, 2015. https://repositorio.ufpe.br/handle/123456789/16120.

Texte intégral

Résumé :

Submitted by Haroudo Xavier Filho (haroudo.xavierfo@ufpe.br) on 2016-03-22T18:32:27Z No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) Dissertação Neyla Alves_Versão digital.pdf: 1629049 bytes, checksum: aa72b7e3881142a178e5534aa4064d95 (MD5)<br>Made available in DSpace on 2016-03-22T18:32:27Z (GMT). No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) Dissertação Neyla Alves_Versão digital.pdf: 1629049 bytes, checksum: aa72b7e3881142a178e5534aa4064d95 (MD5) Previous issue date: 2015-03-02<br>CAPES<br>CNPq

Styles APA, Harvard, Vancouver, ISO, etc.

8

Costa, Matthew R. "FC Receptor-Mediated Activities of Env-Specific Monoclonal Antibodies Generated from Human Volunteers Receiving a DNA Prime-Protein Boost HIV Vaccine: A Dissertation." eScholarship@UMMS, 2010. http://escholarship.umassmed.edu/gsbs_diss/866.

Texte intégral

Résumé :

Human immunodeficiency type 1 (HIV-1) is able to elicit broadly potent neutralizing antibodies in a very small subset of individuals only after several years’ infection and as a result, vaccines that elicit these types of antibodies have been difficult to design. The RV144 trial showed that a moderate protection is possible, which may correlate with antibody dependent cellular cytotoxicity (ADCC) activity. Previous studies in the Lu lab demonstrated that in an HIV-1 vaccine phase I trial, DP6-001, a polyvalent Env DNA prime-protein boost formulation, could elicit potent and broadly reactive, g

Styles APA, Harvard, Vancouver, ISO, etc.

9

Costa, Matthew R. "FC Receptor-Mediated Activities of Env-Specific Monoclonal Antibodies Generated from Human Volunteers Receiving a DNA Prime-Protein Boost HIV Vaccine: A Dissertation." eScholarship@UMMS, 2016. https://escholarship.umassmed.edu/gsbs_diss/866.

Texte intégral

Résumé :

Human immunodeficiency type 1 (HIV-1) is able to elicit broadly potent neutralizing antibodies in a very small subset of individuals only after several years’ infection and as a result, vaccines that elicit these types of antibodies have been difficult to design. The RV144 trial showed that a moderate protection is possible, which may correlate with antibody dependent cellular cytotoxicity (ADCC) activity. Previous studies in the Lu lab demonstrated that in an HIV-1 vaccine phase I trial, DP6-001, a polyvalent Env DNA prime-protein boost formulation, could elicit potent and broadly reactive, g

Styles APA, Harvard, Vancouver, ISO, etc.

10

Chen, Yuxin. "Characterization of Envelope-Specific Antibody Response Elicited by HIV-1 Vaccines: A Dissertation." eScholarship@UMMS, 2001. http://escholarship.umassmed.edu/gsbs_diss/760.

Texte intégral

Résumé :

Despite 30 years of intensive research，an effective human immunodeficiency virus (HIV) vaccine still remains elusive. The desirable immune response capable of providing protection against HIV acquisition is still not clear. The accumulating evidence learned from a recent vaccine efficacy correlate study not only confirmed the importance of antibody responses, but also highlighted potential protective functions of antibodies with a broad repertoire of HIV-1 epitope specificities and a wide range of different antiviral mechanisms. This necessitates a deep understanding of the complexity and dive

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Livres sur le sujet "HIV (Viruses) Gene therapy"

1

Bauer, Gerhard, and Joseph S. Anderson. Gene Therapy for HIV. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Vos, Jean-Michel H., ed. Viruses in Human Gene Therapy. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0555-2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Singwi, Sanjeev. HIV gene therapy using nucleases. Ottawa: National Library of Canada, 1996.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Smith, Clay. Gene Therapy for HIV Infection. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-662-11821-4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Hengge, Ulrich R. Immunotreatment and gene therapy of HIV infection. Bremen: Uni-Med, 2004.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Berkhout, Ben, Hildegund C. J. Ertl, and Marc S. Weinberg, eds. Gene Therapy for HIV and Chronic Infections. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2432-5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Virology, Conference on. HIV and other highly pathogenic viruses. San Diego: Academic Press, 1988.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Canada, Canada Health and Welfare. Therapy and management of CMV in patients with HIV infection/ by Susan M.King. Ottawa: Health and Welfare Canada, 1990.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Lombardi, Rocco Anthony. GAG and ENV trans-dominant mutants for use in ANTI-HIV-1 gene therapy. Ottawa: National Library of Canada, 1996.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Catalán, José. Psychological medicine of HIV infection. Oxford: Oxford University Press, 1995.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Chapitres de livres sur le sujet "HIV (Viruses) Gene therapy"

1

Morgan, Richard A. "Gene Therapy." In Immunology of HIV Infection, 577–94. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-0191-0_30.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Bauer, Gerhard, and Joseph S. Anderson. "Gene Therapy Vectors." In Gene Therapy for HIV, 27–33. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_4.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Bauer, Gerhard, and Joseph S. Anderson. "Principles of Gene Therapy." In Gene Therapy for HIV, 1–8. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Bauer, Gerhard, and Joseph S. Anderson. "History of Gene Therapy." In Gene Therapy for HIV, 9–15. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Bohnlein, Ernst. "HIV Gene Therapy: Current Status and Its Role in Therapy." In Gene Therapy, 91–101. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-72160-1_10.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Bauer, Gerhard, and Joseph S. Anderson. "Principles of HIV Gene Therapy." In Gene Therapy for HIV, 17–25. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_3.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

7

Bauer, Gerhard, and Joseph S. Anderson. "Stem Cells for HIV Gene Therapy." In Gene Therapy for HIV, 35–40. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_5.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Bauer, Gerhard, and Joseph S. Anderson. "Animal Models Used in HIV Gene Therapy." In Gene Therapy for HIV, 41–47. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Bauer, Gerhard, and Joseph S. Anderson. "Manufacturing of a GMP Grade Product for HIV Gene Therapy." In Gene Therapy for HIV, 49–54. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Bauer, Gerhard, and Joseph S. Anderson. "Clinical Applications of HIV Gene Therapy." In Gene Therapy for HIV, 55–62. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0434-1_8.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "HIV (Viruses) Gene therapy"

1

Noy, Ariela. "Abstract PL04-02: HIV malignancies: From despair to gene therapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-pl04-02.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Noy, Ariela. "Abstract PL04-02: HIV malignancies: From despair to gene therapy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-pl04-02.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Miyahara, Hideo, Yuta Kurashina, Yuki Ogawa, Ayumu Kurihara, Tomohiko Yoshida, Hirotaka James Okano, Masato Fujioka, and Hiroaki Onoe. "Hierarchical Hydrogel Drug Delivery System Enables Controlled Release of Adeno-Associated Viruses for Gene Therapy." In 2019 IEEE 32nd International Conference on Micro Electro Mechanical Systems (MEMS). IEEE, 2019. http://dx.doi.org/10.1109/memsys.2019.8870781.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Martini, Sabrina V., Adriana L. Silva, Miquéias Lopes-Pacheco, Hilda Petrs-Silva, Rafael Linden, Patricia R. M. Rocco, and Marcelo M. Morales. "The Efficiency Of Tyrosine-Mutant Adeno-Associated Viruses (AAVs) Serotype Vectors In Pulmonary Gene Therapy." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4975.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Schimpf, Kl, H. H. Brackmann, D. Bock, G. Landbeck, E. Lechler, and H. Vinazzer. "NO ANTI-HIV SEROCONVERSION AFTER REPLACEMENT THERAPY WITH STEAM-TREATED FACTOR VIII CONCENTRATE. A STUDY OF 60 PATIENTS WITH HEMOPHILIA A AND VON WILLEBRAND'S DISEASE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644054.

Texte intégral

Résumé :

Transmission of hepatitis viruses and HIV has proven to be a risk of replacement therapy. Since Dec. 1983 factor VIII concentrates in which viruses are inactivated by steam-treatment (Factor VIII TIM 3 or S-TIM 3) are available for therapy. As they are manufactured by 80% from US plasma it was necessary to prove that they do not transmit HIV. For ethical reasons it is not possible to treat control groups of patients with non-virus- inactivated concentrate. Non-transmission of HIV can, therefore, only be proven if anti-HIV seroconversion does not occur in larger groups of patients treated with

Styles APA, Harvard, Vancouver, ISO, etc.

6

Schimpf, K. l., B. Kraus, W. Kreuz, H. H. Brackmann, F. Haschke, and W. Schramm. "NO ANTI-HIV SEROCONVERSION AFTER REPLACEMENT THERAPY WITH PASTEURIZED F VIII CONCENTRATE. A STUDY OF 151 PATIENTS WITH HEMOPHILIA A OR VON WILLEBRAND'S DISEASE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643973.

Texte intégral

Résumé :

Transmission of hepatitis viruses and HIV has proven to be a risk of replacement therapy in hemophilia. As regards F VIII products a concentrate (Hemate HS or P) in which viruses are inactivated by heat-treatment over 10 hours at 60° C in aqueous solution is available since 1979. Our clinical studies have shown that this product does not transmit HBV and HNANBV. As the product was manufactured by 80% from US plasma it was necessary to prove that it also does not transmit HIV. As it is, for ethical reasons, not possible to treat a control group with non-virus-inactivated F VIII, non-transmissio

Styles APA, Harvard, Vancouver, ISO, etc.

7

Addiego, J. E., P. Bailey, M. Bradley, S. Courter, and M. Lee. "RECOVERY AND SURVIVAL STUDIES OF A NEW FACTOR VIII PRODUCT." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644052.

Texte intégral

Résumé :

Lyophilized protein concentrates are the international treatment of choice to manage bleeding in hemophiliacs. These pooled plasma products, however, expose the recipient of treatment to an increased risk of viral infections. While current manufacturing techniques of these products appear to be effective in eradicating the human immunodeficiency virus (HIV), transmission of other viruses, especially non-A/non-B (NANB) hepatitis, is still a majoor complication of concentrate therapy. Hyland Therapeutics Division Travenol Laboratories, Inc., has developed a new process using the techniques of im

Styles APA, Harvard, Vancouver, ISO, etc.

8

Karges, H. E., P. Fuhge, and N. Heimburger. "PROPERTIES AND VIRUS SAFETY OF A PASTEURIZED ANTITHROMBINIII-CONCENTRATE." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644154.

Texte intégral

Résumé :

The possible occurance of up to now unknown human pathogenic viruses makes it necessary to reconsider thestrategies for the preparation of each plasma protein concentrate used for substitution therapy. Even up to now safe products may be contaminated by infectious particles in the near future. Hence, each procedure for the preparation of such proteins should critically be checked for the elimination of contaminating proteins and should contain an inactivation step for pathogenic agents.Since about 4 decades the pasteurization of albumin in presence of stabilizers has been found to be a safe an

Styles APA, Harvard, Vancouver, ISO, etc.

9

Pasi, K. J., and F. G. H. Hill. "NO EVIDENCE OF HEPATITIS OR HIV TRANSMISSION IN VIRGIN HAEMOPHILIC BOYS TREATED WITH BRITISH HEAT TREATED FACTOR VIII CONCENTRATE (8Y)." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643972.

Texte intégral

Résumé :

HIV and hepatitis virus transmission is of major concern with factor VIII therapy. Non-A, non-B hepatitis (NANBH) has a near 100% incidence in patients previously treated with unheated large pool factor VIII concentrates. NHS heated high purity factor VIII concentrate (8Y) undergoes severe protracted heat treatment of the freeze dried concentrate theoretically sufficient to inactivate hepatitis viruses as well as HIV. Infusions of 22 different batches of 8Y have been given to 18 children with haemophilia A (10 virgin patients; 8 who had only received single donor cryoprecipitate) have been tre

Styles APA, Harvard, Vancouver, ISO, etc.

10

Heimburger, N., P. Fuhge, J. Hilfenhaus, G. Kumpe, and H. E. Karges. "EXPERIMENTAL STUDIES CONCERNING THE VIRUS SAFETY OF PASTEURIZED FIBRINOGEN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644153.

Texte intégral

Résumé :

Fibrinogen is available for substitution in afibrinogenaemic patientssince about 4 decades. However, it soon turned out that those concentrates bear a high risk of transmitting serum hepatitis. Over many years it was not possible to produce safe concentrates of fibrinogen. Hence, the therapy with this protein was limited to vital indications. We have now succeeded to stabilize fibrinogen inaqueous solution for pasteurization over 10 to 20 hours at 60°C.The efficacy of the virus inactivation was tested using various animal viruses. Following results were obtained.Tests in chimpanzees for hepati

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!